Participated · Series A · Feb 2026

Aerska is developing delivery technologies intended to enable systemic delivery of RNA medicines to the brain to treat serious neurological diseases. The company is focused on improving selectivity of RNAi payload delivery and on approaches that could target multiple disease pathways simultaneously. Aerska announced an additional $10M investment from GHIC as part of its Series A, indicating ongoing Series A financing activity. The company positions the GHIC investment as a partnership to advance its platform toward clinical or translational goals. No public operating metrics or founding date were disclosed in the announcement.

Participated · Series A · Jan 2026

Prudentia Sciences provides an artificial-intelligence platform that enables pharmaceutical companies, biotechs, and financial institutions to evaluate breakthrough medicines with greater speed and rigor. The system synthesizes complex clinical signals into actionable insights and uses a human-in-the-loop workflow to facilitate secure, compliant collaboration among buyers, sellers, and intermediaries. Operating as a single, continuously updated source of truth, the platform helps teams make high-stakes acquisition, licensing, and investment decisions more confidently and in a fraction of the traditional time. Its explainable AI and intelligent automation modernize a traditionally fragmented diligence process. With fresh capital in hand, the company plans to expand product capabilities, deepen both technical and non-technical intelligence, and scale commercial operations. Geographic expansion to the Asia-Pacific and Europe is also on the roadmap. Headquartered in Cambridge, Massachusetts, Prudentia has raised $27 million to date, including a $7 million seed round completed in 2024.

Participated · Seed · Jun 2025

Ryght AI delivers an intelligent software platform powered by "AI Site Twins," dynamic data models that replicate every clinical research site worldwide in real time. The system ingests historical performance, patient-demographic and operational data to help life-sciences sponsors and contract research organizations more accurately run trial-feasibility analyses, choose optimal sites, forecast enrollment and streamline site-activation workflows. Built with generative and agentic AI and certified as SOC Type 2 compliant, the platform enables secure, real-time collaboration among sponsors, CROs and research sites. By shortening the traditionally manual processes of site selection and patient recruitment, Ryght AI aims to reduce costly delays and speed new therapies to market. The company is positioning its technology as a foundational layer that integrates with broader enterprise systems used by pharmaceutical and biotech firms. Ryght AI’s go-to-market strategy includes partnerships with global technology and consulting leaders to scale adoption across the industry.

Participated · Series A · Oct 2024

Axonis is developing first-in-class oral small molecules that potentiate KCC2, a CNS chloride transporter crucial for inhibitory neurotransmission. Its lead candidate, AXN-027, is designed to restore functional inhibition and is being advanced into clinical proof-of-concept in patients with epilepsy and pain. The company plans to use its proprietary KCC2 discovery engine to develop next-generation compounds for additional indications including psychiatric and neurodevelopmental disorders. Axonis was spun out from Boston Children’s Hospital, Harvard and Université Laval and is headquartered in Boston, MA. Leadership includes co-founder and CEO Joanna Stanicka, Ph.D., CSO Shane Hegarty, Ph.D., and new appointments for Chief Medical Officer Donald Manning, M.D., Ph.D., and COO Jeff Imbaro. The company has received grant support from multiple public and non-profit sources and will use the recent financing to fund clinical development and pipeline expansion. AXONIS Therapeutics is an emerging biotechnology company based in Cambridge, MA, advancing neuromodulating therapies for central nervous system disorders. Its pipeline focuses on neuron-reviving approaches that enable CNS neurons to resist degeneration, restore excitation/inhibition balance, and regenerate. The company’s primary program centers on upmodulation of the KCC2 protein and has completed proof-of-concept preclinical studies showing reactivation of spared neural tissue at sites of spinal cord injury. Targeted indications include spinal cord injury and epilepsy, with potential applicability to chronic pain, Rett syndrome and broader neurodegenerative conditions. AXONIS has licensed three technologies, including recently discovered methods to prevent neurodegeneration, and is investigating additional methodologies to revive neurons. Financially, the company secured $4 million in seed funding at its operational launch in early 2020, has received non-dilutive awards from the Massachusetts Life Sciences Center and NIH SBIR and two Golden Tickets from Boehringer Ingelheim and Astellas, and just raised additional financing to support clinical advancement and IND-enabling activities. AXONIS Therapeutics is advancing a novel KCC2 upmodulation therapy to reactivate spared neural tissue after spinal cord injury and is also investigating PTEN inhibition to regenerate injured nerve connections. The company has licensed or optioned two technologies from Boston Children’s Hospital to support its preclinical programs. Proceeds from the current financing will enable AXONIS to conduct preclinical studies and expand its team as it moves toward proof-of-concept milestones. AXONIS reports promising proof-of-concept results to date and expects to deliver additional proof-of-concept data in approximately one year. The company has received state and federal non-dilutive funding and other seed investment, and won a Boehringer Ingelheim Golden Ticket that provides one year of free lab space at LabCentral. Leadership includes CEO Joanna Stanicka, PhD, Executive Chair and co-founder Corey Goodman, PhD, and founder Bob Yant; the company is based in Cambridge, MA.

Participated · Equity · Dec 2023

Zafrens provides a platform that allows scientists to create and test hundreds of thousands of potential medicines in a single experiment. The company has demonstrated the value of its platform through collaborations with several pharmaceutical companies across multiple drug classes. Led by CEO Swamy Vijayan, Zafrens focuses on accelerating drug discovery via its high-throughput experimental platform. The new funding will enable the company to expand its capacity. Zafrens also plans to engage in additional partnerships with pharmaceutical companies worldwide. To date, the company has raised a total of USD 31m. Zafrens is a multi-modality drug discovery company commercializing the Z-Screen™ platform, which scales conventional 96-well experiments to 50,000–200,000 wells with integrated imaging and single-cell multi-omic capabilities. The platform resolves complex cellular co-culture interactions at molecular and functional levels, enabling mapping of large CRISPR, CAR-T, mRNA libraries and endogenous heterogeneity to cell behavior, interactions, and secretions. By combining simultaneous functional and molecular profiling with very large chemical libraries, Zafrens aims to reveal hits, structure–activity relationships, and mechanisms of action in a single experiment, compressing multiple traditional discovery stages. The company is advancing an internal pipeline focused on RNA-modulatory small molecules and HLA-agnostic TCR libraries to common cancer mutations and has demonstrated capabilities in CAR-T optimization and bi-specific antibody discovery. Zafrens seeks partnerships in areas where combinatorial libraries of small molecules, genetic perturbations, and cell–cell interactions could produce breakthroughs and expects its high-resolution datasets to inform drug design and patient selection. Financially, Zafrens closed $23 million in financing to optimize the Z-Screen platform and advance its internal pipeline; the company is based in San Diego, CA.